Neucore Bio develops precision genetic medicines using its proprietary FiXE™ platform, which engineers fibroblast-derived exosomes for targeted delivery. This technology offers a non-viral alternative for treating genetic diseases, particularly those affecting the peripheral nervous system. Additionally, the platform provides regenerative solutions for age-related skin decline by stimulating extracellular matrix repair.
Funding
$6.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current genetic medicine delivery methods face limitations in payload size, safety, and the ability to re-dose, hindering their effectiveness in treating complex diseases. Traditional viral delivery approaches can trigger immune responses and have limited capacity for large genetic payloads.
Solution
Neucore Bio is developing next-generation, engineered delivery technologies to improve the precision and efficacy of genetic medicines. Their targeted, non-viral delivery solutions overcome the limitations of viral vectors, enabling the delivery of larger genetic payloads with enhanced safety profiles and the potential for re-dosing. This approach extends the reach of genetic medicine to complex diseases that can benefit from precision therapeutic innovation, ultimately reshaping patient care.
Target Audience
The primary target audience includes medical professionals and researchers focused on developing and applying genetic medicines for the treatment of complex diseases.
Features
- Targeted, non-viral delivery system for genetic payloads
- Overcomes limitations in payload size, safety, and re-dosing associated with viral vectors
- Extends therapeutic reach to complex diseases
- Aims to improve the precision and efficacy of genetic medicines